Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity
NCT05470998Phase 3Completed
- Sponsor
- Tanta University
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of arginine in sickle cell disease (SCD) (2 arms), sponsored by Tanta University. Primary endpoint: Change in tricuspid regurgitant jet velocity at 3 months. Started Jul 2022; status: completed.
02
Drugs
arginine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05470998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470998.